Ramel S, Reid B J, Sanchez C A, Blount P L, Levine D S, Neshat K, Haggitt R C, Dean P J, Thor K, Rabinovitch P S
Department of Surgery, Ersta Hospital, Stockholm, Sweden.
Gastroenterology. 1992 Apr;102(4 Pt 1):1220-8.
Barrett's esophagus is a condition in which the normal stratified squamous epithelium is replaced by metaplastic columnar epithelium that predisposes to the development of esophageal adenocarcinoma. Neoplastic progression in Barrett's esophagus occurs by a multistep process associated with genomic instability and the development of aneuploid cell populations. p53 protein overexpression and allelic deletions on chromosome 17p have been shown to be present in some Barrett's adenocarcinomas, but the stage in neoplastic progression at which p53 protein overexpression develops has not been investigated. To determine the stages in neoplastic progression at which p53 protein overexpression could be detected, biopsy specimens from patients with Barrett's esophagus at all stages of histological progression from Barrett's metaplasia negative for dysplasia to esophageal adenocarcinoma were investigated using a multiparameter flow-cytometric assay. p53 protein overexpression was found in 1 of 21 patients (5%) with Barrett's metaplasia negative for dysplasia, 2 of 13 patients (15%) with Barrett's metaplasia with abnormalities in the indefinite/low-grade dysplasia range, 5 of 11 patients (45%) with high-grade dysplasia, and 8 of 15 patients (53%) with Barrett's adenocarcinoma (P less than 0.01). p53 protein overexpression was found in 9% of patients with Barrett's esophagus who had neither high-grade dysplasia nor adenocarcinoma. Whether or not patients whose biopsy specimens show p53 protein overexpression are at increased risk for progression to adenocarcinoma can be determined by prospective endoscopic surveillance.
巴雷特食管是一种正常的复层鳞状上皮被化生的柱状上皮取代的病症,这种化生的柱状上皮易引发食管腺癌。巴雷特食管的肿瘤进展是一个与基因组不稳定和非整倍体细胞群发展相关的多步骤过程。p53蛋白过表达和17号染色体短臂上的等位基因缺失已在一些巴雷特腺癌中被证实存在,但p53蛋白过表达在肿瘤进展的哪个阶段出现尚未得到研究。为了确定能检测到p53蛋白过表达的肿瘤进展阶段,我们使用多参数流式细胞术分析,对处于从无异型增生的巴雷特化生到食管腺癌的组织学进展各阶段的巴雷特食管患者的活检标本进行了研究。在21例无异型增生的巴雷特化生患者中有1例(5%)发现p53蛋白过表达,13例处于不确定/低级别异型增生范围的巴雷特化生患者中有2例(15%),11例高级别异型增生患者中有5例(45%),15例巴雷特腺癌患者中有8例(53%)(P小于0.01)。在既无高级别异型增生也无腺癌的巴雷特食管患者中,9%发现有p53蛋白过表达。活检标本显示p53蛋白过表达的患者进展为腺癌的风险是否增加,可通过前瞻性内镜监测来确定。